Results 101 to 110 of about 28,674 (272)

Deciphering diverse cell‐death patterns to predict the prognosis and potential therapy target of hepatocellular carcinoma patients

open access: yesVIEW, EarlyView.
Abstract Ninety percent of all primary liver malignancies are hepatocellular carcinomas (HCC), making liver cancer the third most common cause of cancer‐associated mortality. Different patterns of programmed cell death (PCD) are crucial for the survival of tumors, and they might serve as a prognostic marker for HCC.
Lin Ding   +10 more
wiley   +1 more source

ChitoSilkBioPatch: A bio‐inspired wound dressing scaffold for antibiotic‐free diabetic wound management

open access: yesVIEW, EarlyView.
We present ChitoSilkBioPatch, a maleimide‐functionalized chitosan/dACM hydrogel integrated with a stretchable nanopatterned silk mesh to provide intrinsic, antibiotic‐free antibacterial activity and bioactive wound support. The scaffold eliminates S. aureus and P.
Dorsa Dehghan‐Baniani   +12 more
wiley   +1 more source

Integrated multi‐omics analysis reveals metabolic reprogramming as a key driver of angiotensin II‐induced vascular remodeling

open access: yesVIEW, EarlyView.
This study investigates the molecular alterations underlying angiotensin II (Ang II)‐induced vascular remodeling in cardiovascular diseases using a multi‐omics approach. Through data exploration and integrated multi‐omics analysis, our findings reveal that Ang II‐driven vascular injury in vascular smooth muscle cells is mediated by metabolic ...
Yiwei Hu   +8 more
wiley   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern   +8 more
wiley   +1 more source

New Insights into the Geometry and Topology of DNA Replication Intermediates

open access: yesBiology
The regulation of superhelical stress, mediated by the combined action of topoisomerases and fork rotation, is crucial for DNA replication. The conformational changes during DNA replication are still experimentally challenging, mainly due to the rapid ...
Victor Martínez   +7 more
doaj   +1 more source

Imatinib enchances the sensitivity of gastrointestinal stromal tumors to topoisomerase II inhibitors

open access: yesУспехи молекулярной онкологии, 2015
Objective: to study the sensitivity of gastrointestinal stromal tumors (GISTs) to the topoisomerases type II inhibitors and ability of imatinib to enhance GISTs sensitivity to the chemotherapeutic drugs indicated above.Subjects and Methods.
S. V. Boichuk   +3 more
doaj   +1 more source

The Rabl configuration limits topological entanglement of chromosomes in budding yeast. [PDF]

open access: yes, 2019
The three dimensional organization of genomes remains mostly unknown due to their high degree of condensation. Biophysical studies predict that condensation promotes the topological entanglement of chromatin fibers and the inhibition of function.
Arsuaga, Javier   +5 more
core  

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

open access: yesBritish Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy